EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Tale of Two Mechanisms: The p53 Modulator COTI‐2 Is a Zn Metallochaperone

İrem Şimşek, Farsheed Shahbazi-Raz, Michael J Krause, Azam Mohammadzadeh, Maryam Kosar, Peihan Xu, Samra Khan iD, Olena Tykhoniuk, Ashley DaDalt, Deya'a Almasri, Lara K Watanabe, Kaitlyn Breault und 5 weitere

Drug Development Research · 2026

DOI: 10.1002/ddr.70350 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von İrem Şimşek und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, University of Windsor, Windsor, Ontario, Canada. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Metallochaperones, Zinc, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in, or misregulation of, Tp53 are found in approximately 50% of all cancers. p53 functions by ensuring that cells with irretrievably damaged DNA undergo apoptosis. Tp53 mutations often induce conformational changes that inhibit activity; however, small‐molecule chaperones could theoretically restore conformation and activity. COTI‐2, a thiosemicarbazone with orphan‐drug status for ovarian cancer, has proven an effective cytotoxic agent against various cancer cell lines in vitro , exhibited efficacy in vivo , and has demonstrated a good safety profile in Phase 1b human clinical trials. The proposed mechanism, direct engagement and refolding of mutant p53, has been supported by a combination of cell‐based assays and transcriptomics data. Through a combination of experimental and computational approaches, we demonstrate that this is an unlikely mechanism of action, and that COTI ‐2 instead likely acts as a selective, well‐tolerated, zinc chaperone to replace zinc ions lost to p53 mutants' deficient zinc‐binding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53MetallochaperonesZincAntineoplastic AgentsThiosemicarbazonesHumansAnimalsMutationCell Line, TumorApoptosis

Stichwörter der Autor:innen

apoptosischemotherapymetallochaperonepersonalized medicinerestoration‐of‐function

Substanzen

Tumor Suppressor Protein p53MetallochaperonesZincAntineoplastic AgentsThiosemicarbazonesTP53 protein, human

Autor:innen und Institutionen

  • Department of Chemistry and Biochemistry, University of Windsor, Windsor, Ontario, Canada.
  • Binary Star Research Services, LaSalle, Ontario, Canada.
  • Department of Biomedical Sciences, University of Windsor, Windsor, Ontario, Canada.
  • Amaro Therapeutics, New York, New York, USA.
  • WE-Spark Research Institute, Windsor, Ontario, Canada.

ORCID-Profile: Samra Khan, John F Trant

Förderung

  • Natural Sciences and Engineering Research Council of Canada

Zitieren

APA

Şimşek, İ., Shahbazi-Raz, F., Krause, M. J., Mohammadzadeh, A., Kosar, M., Xu, P., Khan, S., Tykhoniuk, O., DaDalt, A., Almasri, D., Watanabe, L. K., Breault, K., Hayward, J. J., Pick, F. S., Ho, R. L., Rawson, J. M., & Trant, J. F. (2026). A Tale of Two Mechanisms: The p53 Modulator COTI‐2 Is a Zn Metallochaperone. Drug Development Research. https://doi.org/10.1002/ddr.70350

Vancouver

Şimşek İ, Shahbazi-Raz F, Krause MJ, Mohammadzadeh A, Kosar M, Xu P, et al. A Tale of Two Mechanisms: The p53 Modulator COTI‐2 Is a Zn Metallochaperone. Drug Development Research. 2026. doi:10.1002/ddr.70350

BibTeX
@article{imek2026,
  author = {Şimşek, İrem and Shahbazi-Raz, Farsheed and Krause, Michael J and Mohammadzadeh, Azam and Kosar, Maryam and Xu, Peihan and Khan, Samra and Tykhoniuk, Olena and DaDalt, Ashley and Almasri, Deya'a and Watanabe, Lara K and Breault, Kaitlyn and Hayward, John J and Pick, Fraser S and Ho, Richard L and Rawson, Jeremy M and Trant, John F},
  title = {A Tale of Two Mechanisms: The p53 Modulator COTI‐2 Is a Zn Metallochaperone},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70350}
}
Kostenlos starten →